Email updates

Keep up to date with the latest news and content from BMC Urology and BioMed Central.

Open Access Research article

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

David Castro-Diaz1*, Pilar Miranda2, Francisco Sanchez-Ballester3, Isabel Lizarraga4, Daniel Arumí5 and Javier Rejas6

Author Affiliations

1 Department of Urology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain

2 Department of Gynaecology, Hospital de Fuenlabrada, Madrid, Spain

3 Department of Urology, Hospital General Universitario de Valencia, Valencia, Spain

4 Medical Unit, Pfizer, S.L.U., Alcobendas (Madrid), Spain

5 Medical Department, Pfizer Inc. Europe, Alcobendas (Madrid), Spain

6 Health Economics and Outcomes Research Department, Pfizer, S.L.U, Alcobendas (Madrid), Spain

For all author emails, please log on.

BMC Urology 2012, 12:19  doi:10.1186/1471-2490-12-19

Published: 26 July 2012



Previous randomized studies have demonstrated that fesoterodine significantly improves the Overactive Bladder (OAB) symptoms and their assessment by patients compared with tolterodine extended-release (ER). This study aimed to assess the effect of aging and dose escalation on patient-reported treatment benefit, after changing their first Overactive Bladder (OAB) therapy with tolterodine-ER to fesoterodine in daily clinical practice.


A post-hoc analysis of data from a retrospective, cross-sectional and observational study was performed in a cohort of 748 OAB adults patients (OAB-V8 score ≥8), who switched to fesoterodine from their first tolterodine-ER-based therapy within the 3–4 months before study visit. Effect of fesoterodine doses (4 mg vs. 8 mg) and patient age (<65 yr vs. ≥65 yr) were assessed. Patient reported treatment benefit [Treatment Benefit Scale (TBS)] and physician assessment of improvement with change [Clinical Global Impression of Improvement subscale (CGI-I)] were recorded. Treatment satisfaction, degree of worry, bother and interference with daily living activities due to urinary symptoms were also assessed.


Improvements were not affected by age. Fesoterodine 8 mg vs. 4 mg provides significant improvements in terms of treatment benefit [TBS 97.1% vs. 88.4%, p < 0.001; CGI-I 95.8% vs. 90.8% p < 0.05)], degree of worry, bother and interference with daily-living activities related to OAB symptoms (p <0.05).


A change from tolterodine ER therapy to fesoterodine with dose escalation to 8 mg in symptomatic OAB patients, seems to be associated with greater improvement in terms of both patient-reported-treatment benefit and clinical global impression of change. Improvement was not affected by age.

Overactive bladder; Fesoterodine; Tolterodine ER; Dose escalation; Age; Patient-reported treatment benefit